Importantly, we show that co-treatment with both Chk1 and GSK3-β inhibitors significantly reduces cell proliferation in four triple negative breast cancer cell lines with different mutations, whereas single treatments had only a minor effect. The gene discussed is GSK3B; the disease is triple-negative breast carcinoma.